Targeting the Role of PRME in Regulating Bone Remodelling During Postmenopausal Osteoporosis

Rajamohanan Jalaja Anish, Aswathy Nair, Vijayalakshmi Bindumadhavan, Neelakanta Pillai Padmakumari Soumya, Arun A. Rauf
Chemistry & biodiversity · 2024 · vol. 21(4) , pp. e202400172 · doi:10.1002/cbdv.202400172 · PMID:38369572 · W4391942465
Lab / animal OA: bronze CC0
🔓 Open OA copy View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by qwen3.7-flash, 2026-10-11 ⓘ

Pterospermum rubiginosum methanolic bark extract protected postmenopausal osteoporosis rats from estrogen deficiency-induced bone loss by regulating remodeling markers and increasing bone mineral density.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

Kariavattom Campus Postmenopausal osteoporosis (PMO) is an old age disorder associated with estrogen deficiency, which reduces bone mass and makes bones more prone to fracture. The present study was proposed to evaluate the invivo osteogenic efficiency of Pterospermum rubiginosum methanolic bark extract (PRME) in the PMO model. Molecular docking studies on transcription factor NFATC1 showed excellent interactions with phytochemical ligands with the lowest binding energies. Female Sprague Dawley (SD) rats (n=24) were divided into four groups, (n=6 each) sham control (Group I) and osteoporotic control (Group II) groups treated with saline, PRME (50 mg/kg/day) and alendronate (10 mg/kg/day) treated with Group III and Group IV (n=6) respectively. The serum tartrate-resistant acid phosphatase 5b and cathepsin-K also exhibited a significant rise after PRME treatment 12.33±2.30 mU/ml and 427.68±46.97 pg/ml, respectively. DEXA results exhibited a remarkable increase in total bone mineral content and density values in PRME-treated animals (0.175±0.002 g/cm2) and (7.95±0.23 g) when compared to osteoporotic control (0.163±0.004 g/cm2) and (6.83±0.34 g). Long-term toxicity study revealed that PRME is non-toxic, up to 100 mg/kg bodyweight for 6 months. Our findings suggest PRME protects osteoporotic SD rats from PMO damage resulting from estrogen deficiency by regulating bone remodelling markers and upregulating BMD indices.

My notes (saved in your browser only)

MeSH descriptors

Osteoporosis, Postmenopausal Osteoporosis, Postmenopausal Animals Biomarkers Bone Remodeling Estrogens Female Humans Molecular Docking Simulation Rats Rats, Sprague-Dawley

Citation neighborhood (no data yet)

We don't have any in-corpus citations linked to this paper yet. This is a recent paper (2024) — citers typically take a year or two to land, and the OpenAlex reference graph may still be filling in.

References (45)

Source provenance

openalex
last seen: 2026-06-10T17:14:06.276822+00:00
pubmed
last seen: 2026-10-08T21:43:02.928383+00:00
License: CC0 · commercial use OK